Literature DB >> 28838352

Syndromic management of sexually transmissible infections in resource-poor settings: a systematic review with meta-analysis of the abnormal vaginal discharge flowchart for Neisseria gonorrhoea and Chlamydia trachomatis.

Caroline van Gemert1, Margaret Hellard1, Catriona S Bradshaw2, Freya J I Fowkes1, Paul A Agius1, Mark Stoove1, Catherine M Bennett3.   

Abstract

BACKGROUND: Syndromic management of sexually transmissible infections is commonly used in resource-poor settings for the management of common STIs; abnormal vaginal discharge (AVD) flowcharts are used to identify and treat cervical infection including Neisseria gonorrhoea and Chlamydia trachomatis. A systematic review and meta-analysis was undertaken to measure the diagnostic test performance of AVD flowcharts, including both World Health Organization (WHO)- and locally-adapted AVD flowcharts.
METHODS: A systematic search of multiple electronic databases was conducted to locate eligible studies published between 1991 and 2014. Flowcharts were categorised into one of 14 types based on: 1) use of WHO guidelines or locally-adapted versions; 2) use of risk assessment, clinical examination or both; and 3) symptomatic entry. Summary diagnostic performance measures calculated included summary sensitivity, summary specificity and diagnostic odds ratio.
RESULTS: Thirty-six studies, including data on 99 flowcharts, were included in the review. Summary sensitivity estimates for WHO flowcharts ranged from 41.2 to 43.6%, and for locally adapted flowcharts from 39.5 to 74.8%. Locally adapted flowcharts performed slightly better than the WHO flowcharts. A difference in performance was not observed between use of risk assessment or clinical examination. The AVD flowchart performed slightly better when it was not restricted to symptomatic women only.
CONCLUSIONS: There was considerable variation in the performance of the AVD flowchart but overall it was a poor diagnostic tool regardless of whether risk assessment or clinical examination was included, or whether the flowchart was WHO or locally developed. Many women were treated unnecessarily and many women with cervical infection were not detected. We caution against their continued use for management of cervical infection.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28838352     DOI: 10.1071/SH17070

Source DB:  PubMed          Journal:  Sex Health        ISSN: 1448-5028            Impact factor:   2.706


  11 in total

1.  Sexually transmitted infection screening to prevent adverse birth and newborn outcomes: study protocol for a randomized-controlled hybrid-effectiveness trial.

Authors:  Andrew Medina-Marino; Susan Cleary; Christina A Muzny; Christopher Taylor; Ashutosh Tamhane; Phuti Ngwepe; Charl Bezuidenhout; Shelley N Facente; Koleka Mlisana; Remco P H Peters; Jeffrey D Klausner
Journal:  Trials       Date:  2022-05-24       Impact factor: 2.728

2.  Experimental Urethral Infection with Neisseria gonorrhoeae.

Authors:  Andreea Waltmann; Joseph A Duncan; Gerald B Pier; Colette Cywes-Bentley; Myron S Cohen; Marcia M Hobbs
Journal:  Curr Top Microbiol Immunol       Date:  2022-03-05       Impact factor: 4.737

3.  Adverse Neonatal Outcomes Associated With Maternal Sexually Transmitted Infections From a Public Health Clinic Cohort in Southern Brazil.

Authors:  Huan Vinh Dong; Mei Leng; Regis Kreitchmann; Jeffrey D Klausner; Karin Nielsen-Saines; Nava Yeganeh
Journal:  J Pediatric Infect Dis Soc       Date:  2022-07-21       Impact factor: 5.235

Review 4.  Diagnosing sexually transmitted infections in resource-constrained settings: challenges and ways forward.

Authors:  Teodora Ec Wi; Francis J Ndowa; Cecilia Ferreyra; Cassandra Kelly-Cirino; Melanie M Taylor; Igor Toskin; James Kiarie; Nancy Santesso; Magnus Unemo
Journal:  J Int AIDS Soc       Date:  2019-08       Impact factor: 5.396

5.  Evaluating the diagnosis and treatment of Chlamydia trachomatis and Neisseria gonorrhoeae in pregnant women to prevent adverse neonatal consequences in Gaborone, Botswana: protocol for the Maduo study.

Authors:  Adriane Wynn; Aamirah Mussa; Rebecca Ryan; Emily Hansman; Selebaleng Simon; Bame Bame; Badani Moreri-Ntshabele; Doreen Ramogola-Masire; Jeffrey D Klausner; Chelsea Morroni
Journal:  BMC Infect Dis       Date:  2022-03-07       Impact factor: 3.090

6.  Developing target product profiles for Neisseria gonorrhoeae diagnostics in the context of antimicrobial resistance: An expert consensus.

Authors:  Cecilia Ferreyra; Jennifer Osborn; Francis Moussy; Emilie Alirol; Monica Lahra; David Whiley; William Shafer; Magnus Unemo; Jeffrey Klausner; Cassandra Kelly Cirino; Teodora Wi
Journal:  PLoS One       Date:  2020-09-01       Impact factor: 3.240

7.  Prevalence, incidence and associated risk factors of STIs during pregnancy in South Africa.

Authors:  Dorothy Chiwoniso Nyemba; Andrew Medina-Marino; Remco P H Peters; Jeffrey D Klausner; Phuti Ngwepe; Landon Myer; Leigh Francis Johnson; Dvora Joseph Davey
Journal:  Sex Transm Infect       Date:  2020-10-01       Impact factor: 3.519

Review 8.  Sexually Transmitted Infections in Pregnancy: A Narrative Review of the Global Research Gaps, Challenges, and Opportunities.

Authors:  Juliana S Grant; R Matthew Chico; Anne Cc Lee; Nicola Low; Andrew Medina-Marino; Rose L Molina; Chelsea Morroni; Doreen Ramogola-Masire; Chrysovalantis Stafylis; Weiming Tang; Andrew J Vallely; Adriane Wynn; Nava Yeganeh; Jeffrey D Klausner
Journal:  Sex Transm Dis       Date:  2020-12       Impact factor: 3.868

9.  Barriers to Access to New Gonorrhea Point-of-Care Diagnostic Tests in Low- and Middle-Income Countries and Potential Solutions: A Qualitative Interview-Based Study.

Authors:  Cecilia Ferreyra; Maël Redard-Jacot; Teodora Wi; Jennifer Daily; Cassandra Kelly-Cirino
Journal:  Sex Transm Dis       Date:  2020-10       Impact factor: 3.868

10.  High Prevalence of Sexually Transmitted Infections in Pregnant Women Living in Southern Brazil.

Authors:  Nava Yeganeh; Regis Kreitchmann; Mei Leng; Karin Nielsen-Saines; Pamina M Gorbach; Jeffrey Klausner
Journal:  Sex Transm Dis       Date:  2021-02-01       Impact factor: 3.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.